6634 ªYÄ£
ªÑ¥»: 3.832»õ
¥Dn·~°È:
¨xŦ¯e¯fªvÀø¤Î¯kµhªvÀø¬ÛÃöÃĪ«¬ã¨s¤Î¶}µo
¸³ºÊ«ùªÑ¤ñ¨Ò: 21.7%(¼W¥[¤¤)
¥~¸ê«ùªÑ¤ñ¨Ò: 0.22%(¼W¥[¤¤)
Ä~Äò©¹¤U¬Ý...!
=============================================================================
²£«~01¡GSNP-610 (ªvÀø¯×ªÕ¨x¯e¯f·sÃÄ)
¾AÀ³¯g: «D°sºë©Ê¯×ªÕ¨xª¢
²£«~Àu¶Õ:
1.¥Ø«e©|µL¼Ð·ÇªvÀøÃĪ«
2.¥«³õº¨£·sÃÄ(First-in-class)
3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x
4.µL¦w¥þ©Ê°ÝÃD
¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C
Ävª§¤O:
1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢
2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯×
3.¥i´£¥X¨uÃĥӽСAÀ³¥Î©óªvÀø§³®W«æ©Ê¯×ªÕ¨x
¬ãµo¶¥¬q:
1.¤w³q¹LUSFDA¤ÎTFDA¼f¬d¶i¤JÁ{§É¤G´Á
2.Á{§ÉÀø®Ä¤Î·sªvÀø¾÷ÂàÅçÃÒ
Àø®Ä¤ÀªR¡G
1.²Ä¤@´ÁÁ{§É¸ÕÅç¡Gµ²ªGÅã¥Ü¤HÅé¨Ï¥Î¦w¥þ¡A©Ê½è¨}¦n
2.²Ä¤G´ÁÁ{§É¸ÕÅç¨ä¤¤¤ÀªR¡G17¦ìNASH ¯f¤H (p=0.009)
=============================================================================
²£«~02¡GSNP-630
¾AÀ³¯g:«D°sºë©Ê¯×ªÕ¨xª¢
²£«~Àu¶Õ:
1.¬°Àu¤Æ(Optimized)¤§·s¤Æ¾Ç¹êÅé(NCE)
2.¥«³õº¨£·sÃÄ(First-in-class)
3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x
4.§@¬°²Ä¤@¥N²£«~¤W¥««áªº±µÄò¦û¦³¥«³õ¤§²£«~
¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C
Ävª§¤O:
1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢
2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯×
3.Àu¤ÆªºÀø®Ä±j«×¡B§@¥Î®É¶¡
4.µL¦w¥þ©Ê°ÝÃD
¬ãµo¶¥¬q:
1.Á{§É«e
2.¹w©w¥Ó½Ð¬ü°êFDAIND¡B§Ö³t³q¹D(fasttrack)¡C
3.¥Ó½Ð¬ü°ê¬ð¯}©ÊªvÀø(breakthrough therapy)ªº»{©w¡C
Àø®Ä¤ÀªR¡G
1. ¥Ø«e¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.05
=============================================================================
²£«~03¡GSNP-810 (µL¨x¬r©Ê¤îµh·sÃÄ¡B¸Ñ¬r¾¯)
¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃÄ (¸Ñ¼öÂíµh¾¯)
²£«~Àu¶Õ:
1.¦w¥þ¤Æ¦Xª«·s²Õ¦X¡BµL¨x¬r©Ê
2.¸Ñ¨M¢¤ÁÂåÀø»Ý¨D (Important urgent unmet medical needs)
3.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥iקï©Î§R°£FDA¨x¬rĵ»y¥i¼W¥[¾¯¶q
¥«³õ: ¤AñQÓi×ô¶È¦b¬ü°ê¤@¦~´N¦³40»õ¬ü¤¸ªº¥«³õ
Ävª§¤O:
1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«
2.¥i§ð¦û¼s¤j¥«³õ¡]NSAID, COX-2 §í¨î¾¯¡BOpioidsÃþ¤îµhÃÄ¥«³õ¡^
3.¥i¬Ù°£¶D³^¶O¡B±Ð¨|°V½m¶O
¬ãµo¶¥¬q:
1.¤w§¹¦¨§C¾¯¶q¡B°ª¾¯¶qÁ{§É¸ÕÅç
2.¤w¥Ó½ÐUSFDA¼Ï纽Á{§É¸ÕÅç¡B±N¥Ó½Ð¬ð¯}©Ê¼f¬d/§Ö³t³q¹D
3.µL¨x¬r©Ê¤AñQÓi×ô¸Ñ¬r¾¯¦¨¤À¡A¤w¥Ó½Ð¬dÅçµn°O¥Î¤§Á{§É¸ÕÅç
=============================================================================
²£«~04¡GSNP-830/ SNP-840
¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃĽƤè(ªvÀø¤¤¡B««×¯kµh)
²£«~Àu¶Õ:
1.µL¨x¬r©Ê¤AñQÓi×ôªº½Æ¤è
2.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥iקï©Î§R°£FDA¨x¬rĵ»y¡A¥i¼W¥[¾¯¶q
¥«³õ: ¤AñQÓi×ô³B¤èÃĦb¬ü°ê¤@¦~´N¦³27»õ¬ü¤¸ªº¥«³õ
Ävª§¤O:
1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«½Æ¤è
2.½Æ¤è¤w¥Ñ¬ü°êFDAn¨D°¾¯¶q§C©ó325²@§J¡A±N¼vÅTÀø®Ä
3.¦³¨Ï¥Î±M§Q¡A¥iקï©Î§R°£FDA¨x¬rĵ»y
4.¥i¼W¥[¤AñQÓi×ô¾¯¶q
¡]¥Ñ325mg ¦^´_¦Ü500 mg¬Æ¦Ü§ó°ª¡A·|¸û¦³®Ä¡^¥H¼W¥[Àø®Ä¡A©Î´î¤ÖOpioids¾¯¶q¡A°§C¦¨Å}°Æ§@¥Î
5.¤GªÌ¾Ü¤@±ÂÅv
6.¥i¼W¥[¥«¦û²v
¬ãµo¶¥¬q:
1.SNP-810¨ú±oÃÄÃÒ«á¡A¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê¸ÕÅç
SNP-830 ¤£¬O ·s¦¨¤À ªº·sÃÄ¡A©Ò¥H¤£»Ýn¶i¦æ²Ä¤@¡A¤G¤Î¤T´ÁÁ{§É´úÅç
µ¥ SNP-810 ®³¨ìÃÄÃÒ«á¡A¥H ·sÀø®Ä½Æ¤è¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê´úÅç ´N¥i¥HÀò±oÃÄÃÒ
=============================================================================
*****************************************************************************
SNP-8 ¨t¦C Àø®Ä¤ÀªR¡G
1. ¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005
1. ¤w¸g§¹¦¨¤§¤HÅé¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005
=============================================================================
*****************************************************************************
¥¼¨Ó¥Ø¼Ð±ÂÅv¥D¤O²£«~¡G
1. ¯×ªÕ¨xÃÄ¡GSNP-610 ©M SNP-630 ¦U¦³ÀuÂI¡A¥Ø¼Ð¬°¥þ²y±ÂÅv
2. ¤îµhÃÄ(OTC): SNP-810, ¥Ø¼Ð¬°¬ü°ê¤Î¥þ²y±ÂÅv
3. ¤îµhÃÄ(³B¤èÃÄ): SNP-830 ¤Î SNP-840, ¦b°Êª«¤W¬Ò¦³¥¿±ªºµ²ªG¡A¥Ø¼Ð¬°¥þ²y±ÂÅv
=============================================================================
*****************************************************************************
¥Ø«e¤½¥q»P°ê»Ú¤j«¬Ãļt¥¿¦b½Í§Þ³N±ÂÅv©M¦X§@p¹º
§Ú¬Ý¹L¤½¥q©xºô©M©Ò´£¨Ñªº¸ê®Æ¡Aı±o¤½¥q«Ü¥Î¤ß¦b¸gÀç¡A¦Ó¥B¸ê®Æ¤]«Ü¸Ô²Ó
¹ï¤½¥qµo®i«Ü¦³¦Û«H¡A¥¼¨ÓªÑ»ùȱo´Á«Ý¡A¦³¾÷·|¬O ¤U¤@Ó ¦X¤@ ÄƪÑ
-----------------------------------------------------------------------------
¥H¤W¸ê®Æ ³£°Ñ¦Ò ªÑªF·|ij¨Æ¿ý.pdf ©M ¤½¥q©xºô (¦³¿³½ìµÛÅwªï¦A²`¤J¬ã¨s»P°Q½×)
¬Ý¬Ý¬O¤£¬O¨«¦X¤@(¥þ³Ó)ªº¸ô¡A·dÓleo±ÂÅvª÷Åo ©Î
¬O¾ÇÄ_¹sªºµÇÃÄ¡An¤@ª½¦Y¡C
===================================
³ø¾É¡G¦bÁ{§É¸ÕÅ礤¡A±µ¨üªvÀøªº±wªÌ¦b²Ä12¶g®ÉªºALT»P°ò½uȬۤñ¦³ÅãµÛ°§C¡A¨S¦³Æ[¹î¨ìÄY«ªº¤£¨}¨Æ¥ó¡C¦¹¥~¡ASNP-630¦³®Ä¥NÁª«ªí²{¥X§ÜÅÖºû¤Æªº¼ç¤O¡A¥]¬AÅãµÛ°§CÅÖºû¤Æ¬ÛÃöªº¥Íª«¼Ð°O(§YCCL4©MCCL5)¡C¦¹¥~¡AFibroScan´ú¶q¥çÅã¥Ü¨ä§ïµ½¨xÅÖºû¤Æªº¥\®Ä¡C
¤£¥Nªí¨S¦³¤£¨}¤ÏÀ³
¤£¬O«¤j§Q¦h «¢
¦pªG½Ã¹L140«e°ª´Nº}«G¤F
¦ü¥G«üªº¬O610
ÄÝ»D¤F
¤£¹L¦³°Ñ¥[¦~·|³ø§i
Á`ºâ¬O¤p§Q¦h
²r¤@¬Ý§Ú¥H¬°¬O±ÂÅv¤F
¦ý¦Ü¤Ö¤]ºâ¬O¦n®ø®§¤F
2.¤½¥q¦WºÙ:ªYÄ£¥ÍÂåªÑ¥÷¦³¤½¥q
3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q
4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î
5.µo¥Í½t¥Ñ:
¥»¤½¥qªvÀø¡u«D°sºë©Ê¯×ªÕ¨xª¢¡v·sÃÄSNP-630¤Î¦³®Ä¥NÁª«¤§°Êª«¸ÕÅç¤Î¤G´Á¤HÅéÁ{§É
¸ÕÅç¨ãÅãµÛªº§Üµoª¢¤Î§ÜÅÖºû¤ÆÀø®ÄÀò2022¦~©ó¬ü°êªi¤h¹yÁ|¦æªº¡u¬ü°êÃľǮa¦~·|¡v
(AAPS 2022 PHARMSCI 360)±µ¨ü¨Ã©óªñ95°êªñ5000¾l¤H¤j·|¤¤¥¿¦¡µoªí¡C
6.¦]À³±¹¬I:¤£¾A¥Î
7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:
¤@¡BSNP-630ªvÀøªº¤p¹«ªº¨xµoª¢¡B¨x¯×ªÕÅÜ©Ê©MÅÖºû¤Æ±o¨ìÅãµÛ§ïµ½¡A¨äALT¤ô¥¡B
ÅÖºû¤Æ¬ÛÃö¥Íª«¼Ð°O¡]§Yalpha-SMA¡BCol1a1¡BCol3a1©MTimp-1¡^§¡ÅãµÛ°§C¡C
SNP-630©M¦³®Ä¥NÁª«³B²zªº¤p¹«ªº¨xŦ¤T»Ä¥Ìªoà§t¶q§¡ÅãµÛ°§C¡C¦bÁ{§É¸ÕÅ礤¡A
±µ¨üªvÀøªº±wªÌ¦b²Ä12¶g®ÉªºALT»P°ò½uȬۤñ¦³ÅãµÛ°§C¡A¨S¦³Æ[¹î¨ìÄY«ªº¤£¨}
¨Æ¥ó¡C¦¹¥~¡ASNP-630¦³®Ä¥NÁª«ªí²{¥X§ÜÅÖºû¤Æªº¼ç¤O¡A¥]¬AÅãµÛ°§CÅÖºû¤Æ¬ÛÃöªº
¥Íª«¼Ð°O(§YCCL4©MCCL5)¡C¦¹¥~¡AFibroScan´ú¶q¥çÅã¥Ü¨ä§ïµ½¨xÅÖºû¤Æªº¥\®Ä¡C
¤G¡BSNP-630ªº¦³®Ä¥NÁª«¤w§¹¦¨²Ä¤G´ÁÁ{§É¸ÕÅç°ª¡B§C¨â¾¯¶q²Õ¦@36¦W¨ü¸ÕªÌ¡A´Á¤¤
¤ÀªRµ²ªGÅã¥Ü¦bÁ{§ÉÀø®Ä«ü¼Ð»P¥¼ªAÃÄ«e¤ñ¸û¡A§e²{·¥ÅãµÛªvÀø®ÄªG¡A¦¨¥\¹F¦¨¦b¯×ªÕ
¨xª¢ªvÀø¤Wªº¥Ø¼Ð¡CSNP-630¥ç¤wÀò¥xÆWFDA®Öã¶i¦æ¨Ã§¹¦¨Á{§É¤@´Á¸ÕÅç¡A¼Æ¾ÚÅã¥Ü
SNP-630¦b¤HÅé¤W¨ã¦³°ª«×¦w¥þ©Ê¡A¥Ø«e¥¿¿n·¥³W¹ºÁ{§É¤G´Á¡CSNP-630¬°ªvÀø¯×ªÕ¨xª¢
·s¦¨¤À·sÃÄ¡A°£¥»¨ÃIJz¬¡©Ê§ó±j¥~¡ASNP-630¥t¦³4Ó¥H¤W¬¡©Ê¥NÁª«¤w¦bÅ餺¸ÕÅç¤W
ÃÒ¹ê¥iªvÀø¯×ªÕ¨xª¢¥B¨ã°ª«×¦w¥þ©Ê¡A¥iª½±µ§@¥Î©ó¨xŦ¡A°§C¨x¯×¡B¨xÅÖºû¤Æ¥Íª«¼Ð
°O¡AªvÀø¯×ªÕ¨xª¢¡C
¤T¡B¥»¤½¥q³z¹L§ë½Z°ê»Úª¾¦W¬ÛÃö»â°ì·|ij¤Î¬ì¾Ç´Á¥Z¡A±j¤Æ·sÃıڸsªº¾Ç³N»ùÈ»P
°ê»Úª¾¦W«×¡C
¥|¡B¥Ø«e¡u«D°sºë©Ê¯×ªÕ¨xª¢¡v©|µL¼Ð·ÇªvÀøÃĪ«¡A¼ç¦b°Ó¾÷Ãe¤j¡ANASH¥«³õ¥¨¤j¡A
¥i¦P®É®e¯Ç¦hÓ·sÃÄ¡C®Ú¾ÚGlobalData 2017¦~5¤ëªº³ø§i¹w´ú¡A¥]¬A¬ü°ê¡A¼Ú·ù¤¤j°ê
®a¡]ªk°ê¡A¼w°ê¡A¸q¤j§Q¡A¦è¯Z¤ú©M^°ê¡^©M¤é¥»ªºNASH¥«³õ¡A¦b¥¼¨Ó¤Q¦~ªº½Æ¦X¦~¼W
ªø²v¹F45¢H¡C¥t®Ú¾Ú¼w·N§Ó»È¦æ¤ÎEvaluate Pharmaªº¹w´ú¡A¥þ²yNASHÃĪ«ªº¥«³õ³W¼Ò
¦b2025¦~¤W¬Ý350»õ~400»õ¬ü¤¸¡C¥Ø«e¥»¤½¥q¥¿¿n·¥´M¨D»P°ê¥~¤j¼t¦@¦P¦X§@©Î±ÂÅvµ¥
¨Æ©y¡C
¤¡B·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A
§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C
read01.com/zh-tw/gRO8Axz.html#.Y0nbvnZByUl
¥þ²yTOP10 CRO¤¤¶È¦³ÃÄ©ú±d¼w©M Charles Riverªº¥D·~ÄÝ©óÁ{§É«eÃĪ«
¥Dn°¼«©ó¦w¥þ©Êµû»ù
°²³]6634¬O¦W¨¬²y·s¨q¡A¨ü¥þ²y¤Q¤j»¨ªù²y¶¤¤¤¨â®a«C·ý¡A¥B¤w³q¹L«e¤Q¤j¸g¬ö¤½¥q¤Î²y±´´ú¸Õ³q¹L¡A
ñ¬ùª÷ªÖ©w¤£¨¥¥i³ë¡A´N«Ý®É¶¡´¦¾å¡C
¤p§Ì¥u³Ñ¤U30%¥ª¥kÀò§Q¡A¤¤¶¡¦³¥X¤@¨Ç¡A³Ìªñ¤S¸É¦^§ó¦h¡C¤£¬O¯«µLªk¥X³Ì°ªÂI
¬Ý¬Ý³o110ªº©³¦³¨S¦³¼µ
¦ý¤½¥q¬£¦pªG¤£§V¤O½Í§P¡A¤j½L³o¼Ë®z¡A¤]¼µ¤£¦í~ÃD¥~¸Ü¡A©ñªÅªo³£ÁÈ¿ú¤F
³o2Ó¤ëÓ¤Hı±o¬O³Ì¦nªº®É¾÷¡A¤£n©M¦X¤@¤@¼Ë¦Y¤F¬u³Ó¡A¥¼¤W¥«ÅܤW¥«¡C¾Ç°ê¤§¤j³»¡A¤T¤Ñ¨ì300¦h¦n¡C
==============================================================
¨ì¦~©³¦n®ø®§ÁÙ¬O¦³¡A©ú¦~¤@©w·|§ó¦n¡I6¨t¤]n®É¶¡¬ã¨s¶i¦æ¡A§»Æ[¬Ý¤½¥q»ùȧë¸ê¡A©ú¦~³ø¹S²v·|¤ñ¤µ¦~°ª¡I©Z¥Õ»¡¨ì²{¦b¬°¤î¤µ¦~³ø¹S²v¤]¬ù4¦¨«Ü¤£¿ù¤F¡CÄ~Äò§a¡I
SNP-610´Á¤¤¤ÀªR...ªì¨B¼Æ¾ÚÀu©óResmetirom.
--------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/7 ¤W¤È 11:26:27²Ä 2199 ½g¦^À³
MGL-3745¼g¿ù§ï¥¿¦¨MGL-3196(Resmetirom)¡C
2022.7.5 ¤û¬z¤j¾Ç¨x¯f¾Ç«È®y±Ð±Â´µ¸¦ªâ«¢¨½´ËÂå¾Ç³Õ¤h: Resmetirom¡§¦³¥i¯à¦¨¬°²Ä¤@Ó³Q§åã¥Î©ó NASH ±wªÌªºÃĪ«¡¨
-------------------------------------------------------------------------------------------------
µ²½×:
³Õ¤h¨S»¡ªº¨Æ¡AResmetirom¬O§_¯u¯à¦¨¬°²Ä¤@Ó³Q§åã¥Î©ó NASH ±wªÌªºÃĪ«¡AÃöÁä¦b¦~©³ªºÅ]¤ýÃö¥d¨x¬ïµ²ªG¦p¦ó?(¤T´Á±on¨x¬ïLiver Biopsy)
-------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/3 ¤W¤È 06:27:54²Ä 2169 ½g¦^À³
¬°¤°»ò¥s¹Ú´K¥H¨Dªºµª®×???
.....
SNP-610´Á¤¤¤ÀªR...ªì¨B¼Æ¾ÚÀu©ó:Ocaliva , MGL3196(Resmetirom¡^, Selonsertib
NASHºC©Ê¯f¡A±wªÌÄ@·Nªø´Á§Ô¨ü·kÄo/äú¤ß¤ÏG/¸¡Âmµ¥°Æ§@¥Î???
Áö¬OºC©Ê¯f¡A¦ý52¶g¤Ó¤[¨o!
--------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2021/11/26 ¤W¤È 09:10:39²Ä 1486 ½g¦^À³
2019/06/27
¤u°Ó§ù¿·»T
ªYÄ£¥ÍÂå¡]6634¡^27¤é«Å¥¬¡AºX¤U«½S¡u·s¤Æ¾Ç¦¨¥÷¡vªvÀø«D°sºë©Ê¯×ªÕ¨xª¢(NASH)²Ä¤G¥N·sÃÄSNP-630¡AÄ~¨ú±o«n«Dµo©ú±M§Q«á¡A¦AÀò±o¬ü°ê±M§Q¡A¦¹±M§Q¦³®Ä´Á©|¦³17¦~¡A³Ì¦h¥i©µªø¦Ü2041¦~¡A¹ï©ó¥¼¨Ó±ÂÅv¦³¨M©w©Ê¼vÅT¡C
...¥Ø«e¤w§¹¦¨¤»¶µ¤HÅéÁ{§É¸ÕÅç¡C¶i¦æ¤¤ªºSNP-6¨t¦C¶}©ñ¦¡Á{§É¤G´Á¬ã¨s¤wÀò±oÅãµÛ¤HÅéÀø®ÄÃÒ¾Ú¡C¾Ú´Á¤¤¤ÀªRµ²ªG¡A NASH¸ÕÅç²Õ¡A¸g [12¶g] ªvÀø«á¡A¨x¥\¯àÀø®Ä«ü¼Ð¤è±¡G¾¢Ói»Ä¤þ଻ÄÂà®ò°ò»Ã¯À(ALT)¡B¾¢Ói»Äf¾L»ÄÂà®ò°ò»Ã¯À(AST)¡B¨Å»Ä²æ²B¡]¨»¨C¡^¡]LDH¡^ÅãµÛ°§C¨ÃÀu©ó«eªu¤j¼tªºÁ{§É¤G´Á¬ã¨sµ²ªG¡F
-------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2020/8/20 ¤U¤È 01:49:07²Ä 299 ½g¦^À³
ª`·N¹Ïªí®É¶¡¶b:SNP-610¬OªvÀø [12¶g ] AST¡BALTÅãµÛ¤U° / Ocaliva ¬O18Ó¤ë¡C
©Ò¥H....
ºq§«Å§GTHR£]¿E°Ê¾¯ASC41ªvÀø¨x¬ï¬¡ÀËÃҹꪺ«D°sºë©Ê¯×ªÕ©Ê¨xª¢52©PII´ÁÁ{§É¸ÕÅ秹¦¨º¨Ò±wªÌµ¹ÃÄ
ASC41¬OÁ{§É¶i«×¤¤°ê²Ä¤@¡B¥þ²y²Ä¤Tªº¥Î©ó«D°sºë©Ê¯×ªÕ©Ê¨xª¢(NASH)ªº¥Òª¬¸¢¿E¯À¨üÅé£] (THR£])¿E°Ê¾¯Ô¿ïÃĪ«¡CASC41 II´ÁÁ{§É¸ÕÅç¬O¥Ñ¤¤°ê¥Íª«§Þ³N¤½¥qµo°_ªº¥Ø«e¶i®i³Ì§ÖªºÀøµ{¬°52©P¤J²Õ¨x¬ï¬¡À˹êNASH±wªÌªºII´ÁÁ{§É¸ÕÅç
Àù¯g¥ÎÃĪ«¦hµLªk³q¹L¦å¸£«Ì½ª¡A¦]¦¹¡A¥i¥Î©óªv療¸£¸~½Fªº¤Æ療ÃĪ«¨ü¨ì·¥¤jªº§½¡C
------------------------------------------------------------------------------------------------
scitechvista.nat.gov.tw/Article/C000003/detail?ID=5026001f-55bb-4855-acc8-7e93b40624b8
¹Í¹Í¹Í¡I²Óµß¤Å¶i¡I³o¸Ì¬O¤j¸£ªºµ´¹ï¨¾¿m¡X¡X¦å¸£«Ì»Ù
¤HÅé§ó¾Ö¦³¡u¤T¤j«Ì»Ù¡v¡A©{¦p°í©T«°Àð¡A¯à©è¾×¥~¬É²§ª«ªº§ð¤J¡C¤T¤j«Ì»Ù¥]¬AL½L«Ì»Ù¡B¸z¹D«Ì»Ù»P¡u¦å¸£«Ì»Ù¡v¡]©ÎºÙ¦å¸£»Ù¾À¡Ablood¡Vbrain barrier¡ABBB¡^¡A¨ä¤¤¡A¦å¸£«Ì»Ù³Ì¬°½ÆÂø¡C
1.¤U¦C¸ÕÅç¥HSNP-810¥i´£°ª¾¯¶q¡A¸ÕÅçµ²ªG???
2.SNP-610/630»PSNP-810ªvÀø¸£Àù¡A¨ã¦³¥[¼®ÄÀ³?
www.turkishneurosurgery.org.tr/pdf/pdf_JTN_2427.pdf (¬Ý¹Ïªí´N¤@²M¤G·¡)
¬ã¨sµ²ªGªí©ú¡A¼³¼ö®§µh¹ï½¦½è¥À²ÓM½F²ÓM¨ã¦³§Ü¸~½F§@¥Î¡A³oºØ¬¡©Ê¬O¥Ñ¤£¦Pªº«H¸¹³q¸ô»¤¾É¡C
-----------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2021/4/27 ¤W¤È 10:07:08²Ä 1066 ½g¦^À³
SNP-610/630»PSNP-810ªvÀø¸£Àù???
---------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2021/4/27 ¤W¤È 09:53:44²Ä 1065 ½g¦^À³
DGAT1¬O¤@个«D±`¦³§Æ±æªv疗恶©Ê胶质¥À细M½F(¤@ºØ³Ì±`¨£¤]¬O³Ì¨ã«Iŧ©Êªº¸£Àù)ªº·sªº药ª«¹v点¡C
------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2021/4/14 ¤W¤È 09:08:28²Ä 1026 ½g¦^À³
2020.10.26¼³¼ö®§µh¹ï½¦½è¥À²ÓM½F²ÓM¼W´Þªº¼vÅT
www.turkishneurosurgery.org.tr/pdf/pdf_JTN_2427.pdf
µ²½×¡G§Ú̪º¬ã¨sµ²ªGªí©ú¼³¼ö®§µh¹ï½¦½è¥À²ÓM½F²ÓM¨ã¦³§Ü¸~½F§@¥Î¡A¨Ã¥B³oºØ¬¡©Ê¬O
¥Ñ¤£¦Pªº«H¸¹³q¸ô»¤¾É¡C...§Ú̵o²{¼³¼ö®§µh´î¤Öªº²ÓM¼W´Þ¨ú¨M©ó [¾¯¶q]©M[«ùÄò®É¶¡]....
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1¶
·|û¡GROGER588910148151 µoªí®É¶¡:2021/4/27 ¤W¤È 09:53:44²Ä 1065 ½g¦^À³
DGAT1¬O¤@个«D±`¦³§Æ±æªv疗恶©Ê胶质¥À细M½F(¤@ºØ³Ì±`¨£¤]¬O³Ì¨ã«Iŧ©Êªº¸£Àù)ªº·sªº药ª«¹v点¡C
2020.8.4
www.x-mol.com/news/457072
ªñ¤é¡A¬ü国«X¥è«X¦{¥ß¤j学肿½F¤¤¤ß³¢¼w¨}±Ð±Âªº¬ã¨s团队¡A¥Hµ{²»³Õ¤h©M¯Õ®p³Õ¤h为¦}¦C²Ä¤@§@ªÌ¦bCell Metabolism杂§Ó¤W发ªí题为¡§Targeting DGAT1 ameliorates glioblastoma by increasing fat catabolism and oxidative stress¡¨ªº¬ã¨s论¤å¡A该¬ã¨sº¦¸´¦¥Ü调节¯×ªÕ»Ä储¦s酶¡X¡X¤G酰°ò¥Ìªo-酰°ò转²¾酶¡]DGAT1¡^¡X¡X¬O¤HÊ^恶©Ê胶质¥À细M½F关键ªº¯×质¥¿Å调节¦]¤l¡A¦}´¦¥ÜDGAT1¬O¤@个«D±`¦³§Æ±æªv疗恶©Ê胶质¥À细M½Fªº·sªº药ª«¹v点¡C
该¬ã¨sº¦¸´¦¥Ü¤F¥Ìªo¤Tà©MDGAT1¦b胶质¥À细M½F¯f¤H组织标¥»¤¤°ªªí达¡A¥BDGAT1ªºªí达¶qÉO¯f¤Hªº¾ãÊ^¦s¬¡时间§e负¬Û关¡]图1¡^
¯u´±¥´ ¤£¥uªÑ»ù 쪫®Æ¤]gg ªo»ùÁÙupup
¤Ï¥¿§Ú¨S©Ð ¨S¿ú «·sÂk0¨Ó»¡ ¤@°_«·s¥Xµo==>§Æ±æ¤pÄ£Åý§Úfire
´«¥y¸Ü¸Ü ¯u¥´¤F ¤îµhÃĤ]n½æ¨ì¤£n¤£n
¤Ï¥¿¬P´Á¤@¨Ó¬Ý¬Ý¥Í§Þ¹ï¤j½L ½Ö²]Àú
=============================================================================
¤pÄ£¤£¬O¤¤¤Ñ¤jÀY¤]¦n ¤£µM·|«ºt®±²±³Q¤Õ©ú¦Y¤Fªºµ²§½
------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/2/22 ¤W¤È 10:55:27²Ä 1725 ½g¦^À³
·|û¡GROGER588910148151 µoªí®É¶¡:2022/2/17 ¤U¤È 12:34:46²Ä 1710 ½g¦^À³
§Ú¥H¬°¬O¥Ñ«Xù´µ¶}¤õ¤ÞÃz¡Aµ²ªG¯Q§JÄõª¯¥M¤H¶Õ¡AºÆª¯¥ý«r¤H!
------------------------------------------------------------------------------------------------
´Á±æ¥_·¥ºµ´¶¤B¦b¥Ï¤FºÆª¯2Óºµ´x«á±¼ÀY´N¨«¡A¤£µM...«u
¬ü«X¤À¶Ç¤j¶q±ÄÁÊ¿ç®g¯fÃĪ«¡B¸K¤ù
------------------------------------------------------------------------------------
¯u®ÖÃz ºG ºG ºG
¤Ñ¦ö¸Uª«¥ÍÆF!
¨ì 2030 ¦~¡A¥þ²y«Dªü¤ùÃþÃĪ«¯kµhªvÀø¥«³õ³W¼Ò±N¹F¨ì 779.1 »õ¬ü¤¸
www.grandviewresearch.com/press-release/global-non-opioid-pain-treatment-market
2022 ¦~ 9 ¤ë¡A¬ü°ê FDA «Øij¦bÃh¥¥ 20 ¶g®ÉÁקK¨Ï¥Î«Dªü¤ùÃþÂíµh¾¯ªvÀø¡A¦]¬°¥¼¥X¥ÍÀ¦¨à¥X²{µÇŦ°ÝÃDªº¥i¯à©Ê«Ü°ª¡C¬F©²ªº¦¹ÃþÁ|±¹¥i¯à·|¨î«DÍrÅé§Üª¢ÃĪº³B¤è¡A±q¦Ó¨î«Dªü¤ùÃþÃĪ«¯kµhªvÀø¥«³õªº¼Wªø¡C
¬F©²ªº¦¹ÃþÁ|±¹¥i¯à·|¨î«DÍrÅé§Üª¢ÃĪº³B¤è
¬F©²ªº¦¹ÃþÁ|±¹¥i¯à·|¨î«DÍrÅé§Üª¢ÃĪº³B¤è
2020.10.15 FDAµo¥¬ÃĪ«¦w¥þĵ°T
www.fda.gov/media/142967/download
¬ü°êFDAµo¥¬Äµ°T¡A§³®W20¶g¥ª¥k©Î§³®W«á´Á¨Ï¥Î«DÃþ©T¾J§Üµoª¢ÃÄ¡]NSAIDs¡^®£¾ÉPL¨à¨u¨£¦ýÄY«ªºµÇŦ°ÝÃD¡A¶i¦Ó¤Þµo¦Ï¤ô¹L¤Ö©M§³®W¨Öµo¯g¡AÀ³ÁקKªA¥Î¡C
«DÍrÅé§Üª¢Ãijq±`¥Î©ó½w¸Ñ¯kµh©M°h¿N¡C¥¦Ì¥]¬Aªü¥q¤ÇªL¡B¥¬¬¥ªâ¡B萘´¶¥Í¡BÂù´âªâ»Ä©M¶ë¨Ó©õ¥¬µ¥ÃĪ«¡C
--------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/9/1 ¤U¤È 08:52:35²Ä 2370 ½g¦^À³
SNP-810µLµÇ¬r©Ê³oÓÀuÂI¡A¹ï©ó·m§ðNSAIDs¡]«DÃþ©T¾J®øª¢¤îµhÃÄ¡^ªº¥«³õ¥÷ÃB¤j¦³§U¤O!
¤îµhÃį}ÃaµÇŦ«OÅ@¾÷¨î!!!
www.commonhealth.com.tw/article/74087
½Ð·V¥Î¤îµhÃÄ¡IµÇŦ¬ì¦WÂå¨Iµh§i¥Õ
-----------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/9/14 ¤W¤È 06:16:17²Ä 2463 ½g¦^À³
¬üªÑ±Y¶^3.94% VS. NASH·§©ÀªÑÃzº¦:Akero (+136.76%) / 89bio Inc(+40%)
«Ü¤£´M±`ªº1¤Ñ.
¨ì©³¦bµ¥¤°»ò ¥xªÑ¬P´Á¤@¤Sn³Q¬üªÑ¸õ¤ô¼v¦V ¤pģģ·|¤£·|¶^¯}120©O??
=============================================
¦³¤@¨Æ¤@ª½¤£¸Ñ¡G¸³¨Æªøªí¥Ü¡A¸Ó¤½¥q¶}µoªºµL¨x¬r©Ê¤AñQÓi×ô¤îµh·sÃÄSNP-810¡AÀò¬ü°êOTC monograph³\¥i¡A¤w¨ú±oNational Drug Code¡]°ê®aÃÄ«~ÅçÃÒ¸¹¡^¤Î¬ü°ê¥«³õ¾P°â¸ê®æ¡C
¤jÃļt±ÂÅvª÷°ª¡A¾P°â¶q¤j¤S¯à°¨¤W¥Îì¨ÓÃÄÃÒÄ~Äò¾P°â¡Aµ¥·sÃÒ¤U¨Ó¦A´«ÃÒ¡A¤À¼íª÷¤]°¨¤W¦³¡A³o¬O¤½¥q±ÂÅvº¿ï²{¦b¦X§@¤j¼tì¦]¡F¬Û«H©¼¦¹¦X§@¨Ã¥BÂX¤j¦X§@¤~¬OºÍ´¼¡C
¥¢¥hªº¦b·sÃÄ®³¦^¨Ó
ªGµM¬O¼ÐÃD¸Ø¤jÂI´N¦³¤HÃö¤ß
§^¥i¨S»¡¤°»ò¤½¥q¤°»òÃıÂÅv¨S¹L®@?????¤]¨S¹ï»ùÃö¨t ¤]¨S¤ºÀ`
±ÂÅv¨S¹L==>§Ö°k§a ¥i¥Nªí©È¨S¹L¨S±ÂÅv´N§Ö½æ ¨S«H¤ß¤]´N½æ ¦³«H¤ß´N¥[½X ¾A¥Î¦b¨C¤@Ó²£·~¨C¤@Ó¤½¥q
ÁÂÁ´£¿ô ²q¤@²q¤£¥Çªk§a ¬Ý¤F¤j¶^ ¤ß±¡¤£¦n ©`¦Ì¤á¤Ö¤F¼Æ¤Qw ³oªO¤Ó§N²M¤£¹³¥_·¥ ¤£¦nª±§r
¥un§OªºªO¤j ¤£n¶Ãcue ´N¨S¨Æ
±ÂÅv¨S¹L¡H
¤½¥q¨S¦³¤½§i
§O³yÁÁ¡H
¦pªG¬O±z©ñ°²°T®§¡H
¥i¯à·|¦Y¤W©x¥q¡H
Ä@½äªA¿é
¤p¶R¤@ÂI
³oÓ¶q 100±i´N©Ô¤F¤@¥b
=======================
ªY ¤µ¤Ñµo¥Í¤F¤°»ò🤔
¤µ¤Ñ´N¾ß´X±i°_¨Ó¦s©ñ
·Qn§Úªº²¼¶Ü¡H
µ¹§Ú±ÂÅv¨ä¾l§K½Í¡C
«¢«¢ ³o´N¬O¦Ì°ê¸ê¥»¥«³õªº§Q®`
¤£¦p§ÚÌ´XÓ©`¦ÌªÑ§ë²¼Åý·sÃĤU¥«(¾Ç¥x·L)¥h¦Ì°ê§a
=================================================
Akero¦b2017¦~³Ð¥ß¡Aû¤u37¤H¡A 9/13Ãzº¦¦¬29.05¡A¬Q¤é¦¬38.31(³Ð·s°ª)¡A¥«È17.78»õ¬ü¤¸¡C
akerotx.com/pipeline/
pipeline´N1¤äÁ{§É¤G´ÁNASHÃĪ«Efruxifermin ¡A§OµL¥Lª«!
Akero Therapeutics «Å¥¬§¹¦¨ÂX¤j´¶³qªÑ¤½¶}µo°â2.3»õ¬ü¤¸(9/15´£¥æ9/19§¹°â)
ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-announces-closing-upsized-public-offering-0/
2022¦~9¤ë15¤é¦V¬ü°êÃÒ¨é¥æ©ö©eû·|´£¥æ¤F»Pµo°â±ø´Ú¬ÛÃö©M´yzªº³Ì²×©ÛªÑ»¡©ú®Ñ¸É¥R©MÀHªþ©ÛªÑ»¡©ú®Ñ¡C
www.163.com/dy/article/HDNED9TI05349C3G.html
...¥þ²yS围内¡A«D°sºë©Ê¯×ªÕ©Ê¨x¯fªº±w¯f²v³£§e现¥X³v渐¼W°ªªº趋势
---------------------------------------------------------------------------
¯×ªÕ¨x¤£¬O¯f-->¦ý¯fÅܬ°¯×ªÕ¨xª¢´N¥i¯àn±zªº©R(¨xŦ³QºÙ¬°¡u¨IÀqªº¾¹©x¡v¡ANASHªì´Á¨S¬Æ¯gª¬¡A±wªÌÃø¥Hµoı¨x¥X°ÝÃD)-->¦A¯fÅܦ¨¨xÅÖºû¤Æ(F1~F3)»P¨xµw¤Æ(F4)´N¬On±zªº©R!
akerotx.com/pipeline/
pipeline´N1¤äÁ{§É¤G´ÁNASHÃĪ«Efruxifermin ¡A§OµL¥Lª«!
------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/9/13 ¤U¤È 10:09:04²Ä 2458 ½g¦^À³
¥Ø«e¬üªÑ¤j¶^ VS. NASH·§©ÀªÑÃzº¦:Akero (+160%) / 89bio Inc(+46%)
------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/9/30 ¤U¤È 10:17:26²Ä 2573 ½g¦^À³
.Akero¦Aº¦13%+³Ð¤µ¦~°ª¡A£¯£¯£¯¡A¶Â¥Õ¦§g¥X³õ¤f¥Õ:§O¤Hªº¥¢±Ñ´N¬O§Úªº§Ö¼Ö?
Experimental: TLC599 LD group:12 mg DSP with 100 µmol PL (1.0 mL)
Experimental: TLC599 HD group:18 mg DSP with 150 µmol PL (1.5 mL)
Placebo Comparator: 1.5 mL normal saline
2.¥x·LÅéTLC599 ¤T´Á:
Experimental: TLC599:TLC599 (1mL) IA injection
Active Comparator: Dexamethasone sodium phosphate 4mg (1mL) IA injection
Placebo Comparator: Normal saline (1mL) IA injection
--------------------------------------------------------------------------------------------
TLC599¤D¥x·LÅé¿W®a[ªø®Ä½wÄÀ]°t¤è¤§¦a¶ë¦ÌªQÁC»Ä¶uÃĪ«(Dexamethasone sodium phosphate)
ÃĪ«¥Øªº¦bÅçÃÒ6Ӥ몺[ªø®Ä½wÄÀ]®ÄªG¡A«ç»ò¤£¦b¤G´ÁÁ{§É´N¥ÎDexamethasone sodium phosphate°µ¹ï·Ó?
Endo says osteoarthritis pain candidate failed in late-stage study
seekingalpha.com/news/3886056-endo-says-osteoarthritis-pain-candidate-failed-in-late-stage-study
´º³Í³o¨Ç·s»D¤§«eª£¹L¤F ³o¤]¯à¼Q40% ¤ºÀ`¤Ó²r¤F
¤£n³Q¶W¨®¤F!!
========================
§Oºô³£¦bª`·N·sÃĤF ¤£ª¾¬O¦n¬OÃa
¬Ý¬Ý¨º¨Ç¤£·Çªº¦Ñ¿é